Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 2,250 shares at $21.63 ($47K) on 2023-05-05, disclosed to the SEC on 2023-05-09.
Scheduled sale ($47k) by CHIEF SCIENTIFIC OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.79 | 2,045 | $43K | 90.6% |
| 2 | $21.63 | 205 | $4K | 9.4% |
| Total | $20.87 avg | 2,250 | $47K | 100% |
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |